Tech Company Financing Transactions
Bonti Funding Round
RBV Capital, City Hill Ventures and Colt Ventures participated in a $11.7 million Series B funding round for Bonti. The financing was announced on 4/21/2017.
Transaction Overview
Company Name
Announced On
4/21/2017
Transaction Type
Venture Equity
Amount
$11,700,000
Round
Series B
Investors
Proceeds Purpose
Proceeds from the round will be used to continue developing EB-001, a unique botulinum neurotoxin, for its targeted aesthetic and therapeutic indications with multi-billion dollar addressable market opportunities.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
4921 Birch St. 120
Newport Beach, CA 92660
USA
Newport Beach, CA 92660
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Bonti, based in Newport Beach, California, is a rapidly emerging biotechnology company founded by world class neurotoxin experts with proven success at Allergan, one of the Fortune 500 fastest growing pharma companies.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Fauad Hasan
Chief Medical Officer
Susan Abushakra
Chief Operating Officer
Wajdie Ahmad
Co-Founder
Mike Jarpe
VP - Regulatory Affairs
James Stonecypher
Browse more venture capital transactions:
Prev: 4/21/2017: Getaround venture capital transaction
Next: 4/21/2017: Cardiac Insight venture capital transaction
Share this article
About Our Venture Capital Transactions Database
Our team works diligently to report on every notable VC transaction. VC investment data records reported here are sourced from a variety of public sources. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs